Heron Therapeutics (HRTX) Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Heron Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HRTX shares.
View HRTX analyst ratings or view top-rated stocks.

2 Wall Street research analysts have issued 12 month price objectives for Heron Therapeutics' stock. Their HRTX share price forecasts range from $5.50 to $10.00. On average, they predict the company's share price to reach $7.50 in the next year. This suggests a possible upside of 541.0% from the stock's current price.
View analysts price targets for HRTX or view top-rated stocks among Wall Street analysts.

Heron Therapeutics' stock was trading at $2.50 at the start of the year. Since then, HRTX stock has decreased by 53.2% and is now trading at $1.17.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our HRTX earnings forecast.

Heron Therapeutics, Inc. (NASDAQ:HRTX) released its earnings results on Thursday, March, 23rd. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.08. The biotechnology company earned $30 million during the quarter, compared to analysts' expectations of $27.24 million. Heron Therapeutics had a negative trailing twelve-month return on equity of 21,127.62% and a negative net margin of 132.57%. The company's quarterly revenue was up 44.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.54) EPS.

ETFs with the largest weight of Heron Therapeutics (NASDAQ:HRTX) stock in their portfolio include Jacob Forward ETF (JFWD), Simplify Propel Opportunities ETF (SURI) and Invesco Nasdaq Future Gen 200 ETF (QQQS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Heron Therapeutics investors own include Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Editas Medicine (EDIT), Immunomedics (IMMU), bluebird bio (BLUE), AT&T (T) and Amarin (AMRN).

Heron Therapeutics trades on the NASDAQ under the ticker symbol "HRTX."

Heron Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.88%), JPMorgan Chase & Co. (5.92%), Great Point Partners LLC (4.88%), Palisade Capital Management LP (3.33%), ArrowMark Colorado Holdings LLC (2.80%) and State Street Corp (2.14%). Insiders that own company stock include Craig A Johnson, David Leslie Szekeres, Kimberly Manhard and Waage Christian.
View institutional ownership trends.

Shares of HRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HRTX stock can currently be purchased for approximately $1.17.

Heron Therapeutics (NASDAQ:HRTX) has a market capitalization of $140.06 million and generates $107.67 million in revenue each year. The biotechnology company earns $-182,020,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis.

The company employs 302 workers across the globe.

Heron Therapeutics' mailing address is 4242 CAMPUS POINT COURT SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.herontx.com. The biotechnology company can be reached via phone at (858) 251-4400, via email at ir@herontx.com, or via fax at 650-365-6490.